|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Doebele RC, Drilon A, Paz-Ares L, Siena S,
Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al:
trial investigators: Entrectinib in patients with advanced or
metastatic NTRK fusion-positive solid tumours: Integrated analysis
of three phase 1-2 trials. Lancet Oncol. 21:271–282.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang-Gillam A, Li CP, Bodoky G, Dean A,
Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et
al: NAPOLI-1 Study Group: Nanoliposomal irinotecan with
fluorouracil and folinic acid in metastatic pancreatic cancer after
previous gemcitabine-based therapy (NAPOLI-1): A global,
randomised, open-label, phase 3 trial. Lancet. 387:545–557.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Williet N, Saint A, Pointet AL, Tougeron
D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N,
Hautefeuille V, et al: Folfirinox versus
gemcitabine/nab-paclitaxel as first-line therapy in patients with
metastatic pancreatic cancer: A comparative propensity score study.
Therap Adv Gastroenterol. 12(1756284819878660)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Matsumoto T, Kurioka Y, Okazaki U, Matsuo
Y, Kimura S, Miura K, Tsuduki T, Takagi S, Takatani M and Morishita
H: FOLFIRINOX for advanced pancreatic cancer patients after
Nab-paclitaxel plus gemcitabine failure. Pancreas. 49:574–578.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lee JC, Woo SM, Shin DW, Kim J, Yang SY,
Kim MJ, Kim JW, Kim JW, Lee WJ, Cha HS, et al: Comparison of
FOLFIRINOX and gemcitabine plus Nab-paclitaxel for treatment of
metastatic pancreatic cancer: using Korean pancreatic cancer
(K-PaC) registry. Am J Clin Oncol. 43:654–659. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vogl UM, Andalibi H, Klaus A, Vormittag L,
Schima W, Heinrich B, Kafka A, Winkler T and Öhler L:
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line
treatment in patients with unresectable adenocarcinoma of the
pancreas: Does sequence matter? BMC Cancer. 19(28)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pusceddu S, Ghidini M, Torchio M, Corti F,
Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo
M, et al: Comparative effectiveness of gemcitabine plus
Nab-paclitaxel and FOLFIRINOX in the first-line setting of
metastatic pancreatic cancer: a systematic review and
meta-analysis. Cancers (Basel). 11(E484)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Itoh T, Takemoto I, Itagaki S, Sasaki K,
Hirano T and Iseki K: Biliary excretion of irinotecan and its
metabolites. J Pharm Pharm Sci. 7:13–18. 2004.PubMed/NCBI
|
|
15
|
Kang J, Lee SH, Choi JH, Paik WH, Ahn DW,
Jeong JB, Ryu JK and Kim YT: Folfirinox chemotherapy prolongs stent
patency in patients with malignant biliary obstruction due to
unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int.
19:590–595. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bonnet E, Mastier C, Lardy-Cléaud A,
Rochefort P, Sarabi M, Guibert P, Cattey-Javouhey A, Desseigne F
and de La Fouchardière C: FOLFIRINOX in patients with peritoneal
carcinomatosis from pancreatic adenocarcinoma: A retrospective
study. Curr Oncol. 26:e466–e472. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kinoshita J, Fushida S, Tsukada T, Oyama
K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I,
et al: Comparative study of the antitumor activity of
Nab-paclitaxel and intraperitoneal solvent-based paclitaxel
regarding peritoneal metastasis in gastric cancer. Oncol Rep.
32:89–96. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kondo T, Kanai M, Kou T, Sakuma T,
Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, et al:
Association between homologous recombination repair gene mutations
and response to oxaliplatin in pancreatic cancer. Oncotarget.
9:19817–19825. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill
S, Ruan JY and Cheung WY: Eligibility of metastatic pancreatic
cancer patients for first-line palliative intent nab-paclitaxel
plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 40:507–511.
2017.PubMed/NCBI View Article : Google Scholar
|
